Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

Classifica tra le azioni #1971
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Prezzo delle azioni
$458.30
Capitalizzazione di mercato
$10.59B
Variazione (1 giorno)
-1.98%
Variazione (1 anno)
6.58%
Paese
US
Scambia Madrigal Pharmaceuticals, Inc. (MDGL)

Categoria

Healthcare
Storico del prezzo dell'azione per Madrigal Pharmaceuticals, Inc. (MDGL)
Prezzo di chiusura più alto: $472.49 il 2026-10-01

Prezzo di chiusura più basso: $322.31 il 2007-02-01
Storico del prezzo dell'azione di Madrigal Pharmaceuticals, Inc. dal 2007 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -11.55%
2025 85.56%
2024 36.19%
2023 46.99%
2022 95.20%
2021 -32.68%
2020 16.63%
2019 -6.63%
2018 32.71%
2017 414.16%
2016 26.67%
2015 -87.18%
2014 -42.14%
2013 -44.12%
2012 87.26%
2011 -19.61%
2010 10.34%
2009 1.71%
2008 -25.83%
2007 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$527.18 23.67%
US
$251.29 814.11%
US
$138.33 -3.31%
AU
$890.85 6.72%
NL
$752.87 7.40%
CH